**7. Conclusion**

The diversity of ABD results from diversity of recognizable epitopes of adhesive, desmosomal, hemidesmosomal and basement membrane antigens that interact playing complicated role in securing tissue integrity, intercellular communication and skin growth. Aberrant adhesive molecule expression via epitope spreading, bystander effect and various signaling pathways, may contribute to increased risk of developing cancer and its further prognosis. The altered expression of adhesion complex molecules is thought to be vital for carcinoma motility and invasion. The conjunction of malignancy and ABD phenomenon still remains an area of interest of researchers worldwide, as it may benefit in development of more specific diagnostic tests and precise therapeutic strategies.

[2] Franks AL, Slansky JE. Multiple associations between a broad spectrum of autoim‐ mune diseases, chronic inflammatory diseases and cancer. Anticancer Research

Malignancy in Relation to Autoimmune Blistering Dermatoses: Molecular and Clinical Aspects

http://dx.doi.org/10.5772/55240

193

[3] Vendramini-Costa DB, Carvalho JE. Molecular Link Mechanisms between Inflamma‐

[4] Gornowicz-Porowska J, Bowszyc-Dmochowska M, Dmochowski M. Autoimmunitydriven enzymatic remodeling of the dermal-epidermal junction in bullous pemphi‐

[5] Wolff K, Johnson R, Suurmond R. Fitzpatrick's Color Atlas & Synopsis of Clinical Dermatology. - 5th ed. United States of America: McGraw-Hill Professional; 2005. [6] Lutkowska A, Pietkiewicz P, Szulczyńska-Gabor J, Gornowicz J, Bowszyc-Dmo‐ chowska M, Dmochowski M. Gluteal skin is not an optimal biopsy site for direct im‐ munofluorescence in diagnostics of dermatitis herpetiformis. A report of a case of

[7] Nguyen VT, Ndoye A, Shultz LD, Pittelkow MR, Grando SA. Antibodies against ker‐ atinocyte antigens other than desmogleins 1 and 3 can induce pemphigus vulgaris-

[8] Langan SM, Smeeth L, Hubbard R, Fleming KM, Smith CJP, West J. Bullous pemphi‐ goid and pemphigus vulgaris--incidence and mortality in the UK: population based

[9] Hashimoto T, Amagai M, Garrod DR, Nishikawa T. Immunofluorescence and immu‐ noblot studies on the reactivity of pemphigus vulgaris and pemphigus foliaceus sera

[10] Dańczak-Pazdrowska A, Bowszyc-Dmochowska M, Wolnik-Trzeciak G, Dmochow‐ ski M. IgG, IgG1 and IgG4 deposits in hair follicles in relation to IgG, IgG1 and IgG4 antibodies to desmogleins in pemphigus. Dermatologia Kliniczna 2004;6:207–13. [11] Hallaji Z, Mortazavi H, Lajevardi V, Tamizifar B, AmirZargar A, Daneshpazhooh M, Chams-Davatchi C. Serum and salivary desmoglein 1 and 3 enzyme-linked immuno‐ sorbent assay in pemphigus vulgaris: correlation with phenotype and severity. Jour‐ nal of the European Academy of Dermatology and Venereology 2010;24:275–80. [12] Frew JW, Murrell DF. Paraneoplastic pemphigus (paraneoplastic autoimmune multi‐ organ syndrome): clinical presentations and pathogenesis. Dermatologic Clinics

[13] Zillikens D, Rose PA, Balding SD, Liu Z, Olague-Marchan M, Diaz LA, Giudice GJ. Tight clustering of extracellular BP180 epitopes recognized by bullous pemphigoid

autoantibodies. Journal of Investigative Dermatology 1997;109:573–9.

with desmoglein 3 and desmoglein 1. Epithelial Cell Biology 1995;4:63–9.

tion and Cancer. Current Pharmaceutical Design 2012;18:3831–52.

goid and dermatitis herpetiformis. Autoimmunity 2012;45:71–80.

dermatitis herpetiformis Cottini. Dermatologia Kliniczna 2009;11:31–3.

like lesions. Journal of Clinical Investigation 2000;106:1467–79.

cohort study. BMJ 2008;337:a180–a180.

2011;29:419–425, viii.

2012;32:1119–36.

Concomitance of malignancy and these serious clinical conditions may dramatically decrease the patient survivorship. The wise clinician ought to trace potential malignancy in each and every one of the patients with ABD, regardless of deceptive lack of "paraneoplastic" epithet in the currently used misleading nosology for majority of those dermatoses, as such an associa‐ tion between those two groups of entities, was demonstrated not to be rare. Therefore, the diagnosis of ABD should be followed not only by screening, but also monitoring/periodical checking for malignancies. Moreover, the replacement of indiscriminate immunosuppressive therapy by individualized targeted therapy should be recommended. There is burning need for awareness of such coexistence also among oncologic patients, as ADB may herald the recurrence of malignancy.
